Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pictilisib
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pictilisib is an investigational small molecule inhibitor targeting class I phosphatidylinositol 3-kinases (PI3K), with potent activity against the PI3Kα and PI3Kδ isoforms. It was developed for the treatment of various solid tumors and hematological malignancies. Pictilisib acts by inhibiting the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in cancer and plays a critical role in cell growth, survival, proliferation, motility, and metabolism. The drug has shown promising responses in clinical trials for several cancer types including breast cancer (especially hormone receptor-positive subtypes), ovarian cancer, myeloma, melanoma, non-Hodgkin lymphoma, and certain gastrointestinal cancers. Pictilisib has been evaluated both as monotherapy and in combination with other agents such as fulvestrant or paclitaxel[1][5][6][8].
- Other names
- pictilisib
02
Targets
PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)
Beyond the preview
Go deeper on pictilisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pictilisib.